Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Debt / NOTE 2.500% 9/1
-
Market price (% of par)
-
101.47%
-
Total 13F principal
-
$228,513,000
-
Principal change
-
+$1,279,000
-
Total reported market value
-
$232,919,000
-
Number of holders
-
29
-
Value change
-
+$4,189,127
-
Number of buys
-
14
-
Number of sells
-
7
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 as of Q4 2020
As of 31 Dec 2020,
TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 was held by
29 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$228,513,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, DeepCurrents Investment Group LLC, CITADEL ADVISORS LLC, SILVERBACK ASSET MANAGEMENT LLC, ADVENT CAPITAL MANAGEMENT /DE/, OAKTREE CAPITAL MANAGEMENT LP, Opti Capital Management, LP, Context Capital Management, LLC, Verition Fund Management LLC, and CAPSTONE INVESTMENT ADVISORS, LLC.
This page lists
29
institutional bondholders reporting positions
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.